secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2023-06-20T23:59:59+00:00
Accession:  0001193125-23-169508
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx receives FDA clinical hold on CART-ddBCMA after patient death in Phase 2 trial
--------------------------------------------------------------------------------

- FDA placed clinical hold on CART-ddBCMA IND for relapsed/refractory multiple myeloma on June 16, 2023, after a recent patient death.
- FDA cleared continued dosing of patients who have already undergone lymphodepletion.
- Company believes limitations on bridging therapy are a contributing factor; working with FDA to amend protocol to expand options.
- Manufacturing success rate remains 100% while ramping Lonza to full scale; 14 clinical sites opened and enrollment tracking to expectations.
- Partners include Kite Pharma; CEO expresses confidence in best-in-class potential based on clinical profile to date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312523169508/0001193125-23-169508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312523169508/d443230d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-169508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer